Quick Guide to Recent Changes We’ve Made to G2’s Reports
A new name comes with Lab Industry Advisor, but the goal of helping labs remains the same.
The latest regulatory, legal, compliance, and technology news for labs and pathology practices.
A new name comes with Lab Industry Advisor, but the goal of helping labs remains the same.
Last week saw two key lab-related cases, with the biggest involving a fraud scheme relating to cancer genetic testing.
HHS orders arbitrators to go back to resolving payment disputes between providers and payors under the No Surprises Act.
This week’s cases involved false billing allegations related to urine drug testing, as well as diagnostic imaging false claims and fraud.
Recently released AACC document covers newly updated screening guidelines as well as information on surveillance and diagnosis.
Enzo recently announced that it is selling its lab division to LabCorp for $146 million in cash.
A recently released report estimates that the US market will grow at a CAGR of 4.2 percent over the next seven years.
The owners face fraud charges in two different schemes, one involving urine drug testing and one involving COVID-19 testing.
New Advisory Opinion 23-01 is similar to other arrangements the OIG has approved in the past.
If Congress won’t do it, we will, the FDA says of laboratory developed test reform.
Recent OIG report says Medicare could have saved up to $215.8 million on at-risk payments for G0483 definitive drug tests.